Overview

  • Product name
    Sorafenib
  • Description
    Potent multikinase inhibitor
  • Alternative names
    • BAY 43-9006
    • Nexavar
  • Biological description

    Potent multikinase inhibitor that targets the RAF/MEK/ERK pathway in tumor cells, and tyrosine kinases involved in tumor angiogenesis, oncogenesis, and maintenance of the tumor microenvironment. Inhibits Raf-1, B-Raf, VEGFR-2, VEGFR-3, PDGFR-β, Flt3, c-KIT and FGFR-1 (IC50 values are 6 nM, 22 nM, 90 nM, 20 nM, 57 nM, 58 nM, 68 nM and 580 nM in cell-free assays, respectively).

  • Purity
    > 98%

Properties

  • Chemical name
    4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
  • Molecular weight
    464.82
  • Chemical structure
    Chemical Structure
  • Molecular formula
    C21H16ClF3N4O3
  • CAS Number
    284461-73-0
  • PubChem identifier
    216239
  • Storage instructions
    Shipped at Room Temperature. Store at -20°C. Store under desiccating conditions.
  • Solubility overview
    Soluble in DMSO to 100 mM
  • Handling

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • SMILES
    CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
  • Source

    Synthetic

References

This product has been referenced in:
  • Davoudi ET  et al. Sorafenib in renal cell carcinoma. Pak J Pharm Sci 27:203-8 (2014). Read more (PubMed: 24374450) »
  • Liu L  et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851-8 (2006). Read more (PubMed: 17178882) »
  • Adnane L  et al. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407:597-612 (2006). Read more (PubMed: 16757355) »
  • Wilhelm SM  et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-109 (2004). Read more (PubMed: 15466206) »

See 0 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab141966.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"

Sign up